Semantic start-up Semantelli has announced “the release of Facebook AETracker- a unique solution to help pharmaceutical companies maintain Facebook pages after the August 15th deadline imposed by the social networking giant. In May this year, Facebook announced it will enable public feedback and comments to encourage bidirectional dialogue on pages created by pharmaceutical companies, ending an exclusive privilege it had given pharma since facebook launched its business pages.”

The article continues, “Facebook AETracker helps pharma companies track Adverse Drug Reactions and Product Misinformation in user comments on company sponsored Facebook pages in real-time with additional workflow to report them to FDA. ‘Our ability to track Adverse Events, Product Misinformation and other potential threats real-time in Facebook, Twitter and other social media channels should make FDA happy. This allows pharma companies stay on Facebook, and at the same time frees them to further explore the power of social media without waiting for guidelines or fearing regulatory impacts. Social Media is just another channel. We should treat it as such. It can play a major role in improving health outcome.’ said Siva Nadarajah CEO of Semantelli.”

Learn more here.

Image: Courtesy Semantelli